AVE 0.00% 0.2¢ avecho biotechnology limited

Ann: Phosphagenics Newsletter - August 2018, page-3

  1. 15,643 Posts.
    lightbulb Created with Sketch. 5711
    Yep the key points say it all I believe @turps :

    Key Points:
     TPM® Oxymorphone Patch pre-IND, FDA face-to-face meeting confirmed for December ‘18.
     Injectable candidates continue to progress – development candidates on track for 2018 Tox
     Multiple companies undertaking due diligence on Animal Health Business.
     Strong Vital ET sales on forecast for 2018
     Independent research coverage rates POH a ‘Buy’ with target 8-9 cents share price
     Mylan Arbitration Outcome: still to come.
    Last edited by col69: 13/08/18
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.